NeoCast
Development- Indications
- Chronic subdural hematomas, Hypervascular tumors, Neurovascular bleeding
Company intelligence / Profile preview
Arsenal Medical has demonstrated first-in-human results with NeoCast, meeting primary endpoints and enabling significant distal penetration of hypervascular brain tumors. Preclinical studies show superior vessel occlusion compared to market-leading agents. ResQFoam is FDA-designated as a breakthrough device for controlling non-compressible abdominal hemorrhage and is advancing through clinical development
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arsenal Medical.